Terms: = Lung cancer AND NTRK1, ENSG00000198400, 4914, P04629, TRK1, MTC, DKFZp781I14186, p140-TrkA, TRKA, TRK AND Treatment
152 results:
1. Estimating the Prognostic Value of the Ntrk Fusion Biomarker for Comparative Effectiveness Research in The Netherlands.
Santi I; Vellekoop H; M Versteegh M; A Huygens S; Dinjens WNM; Mölken MR
Mol Diagn Ther; 2024 May; 28(3):319-328. PubMed ID: 38616205
[TBL] [Abstract] [Full Text] [Related]
2. Precision nanomedicine to treat non-small cell lung cancer.
Dessai A; Nayak UY; Nayak Y
Life Sci; 2024 Jun; 346():122614. PubMed ID: 38604287
[TBL] [Abstract] [Full Text] [Related]
3. Outcomes and costs with the introduction of robotic-assisted thoracic surgery in public hospitals.
Betser L; Le Bras A; Etienne H; Roussel A; Bobbio A; Al-Zreibi C; Martinod E; Alifano M; Castier Y; Assouad J; Durand-Zaleski I; Mordant P
J Robot Surg; 2024 Mar; 18(1):124. PubMed ID: 38492119
[TBL] [Abstract] [Full Text] [Related]
4. Patient-reported outcomes in advanced NSCLC before and during the COVID-19 pandemic: Real-world data from the German prospective CRISP Registry (AIO-trk-0315).
Sebastian M; Eberhardt WEE; von der Heyde E; Dörfel S; Wiegand J; Schiefer C; Losem C; Jänicke M; Fleitz A; Zacharias S; Kaiser-Osterhues A; Hipper A; Dietel C; Bleckmann A; Benkelmann R; Boesche M; Grah C; Müller A; Griesinger F; Thomas M;
Int J Cancer; 2024 Jun; 154(11):1967-1978. PubMed ID: 38329180
[TBL] [Abstract] [Full Text] [Related]
5. Repotrectinib: First Approval.
Dhillon S
Drugs; 2024 Feb; 84(2):239-246. PubMed ID: 38279972
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic and predictive biomarkers in non-small cell lung carcinoma.
Odintsov I; Sholl LM
Pathology; 2024 Mar; 56(2):192-204. PubMed ID: 38199926
[TBL] [Abstract] [Full Text] [Related]
7. Updated efficacy and safety of entrectinib in Ntrk fusion-positive non-small cell lung cancer.
Cho BC; Chiu CH; Massarelli E; Buchschacher GL; Goto K; Overbeck TR; Loong HHF; Chee CE; Garrido P; Dong X; Fan Y; Lu S; Schwemmers S; Bordogna W; Zeuner H; Osborne S; John T
Lung Cancer; 2024 Feb; 188():107442. PubMed ID: 38171156
[TBL] [Abstract] [Full Text] [Related]
8. A clinical perspective on ectopic Cushing's syndrome.
Ragnarsson O; Juhlin CC; Torpy DJ; Falhammar H
Trends Endocrinol Metab; 2024 Apr; 35(4):347-360. PubMed ID: 38143211
[TBL] [Abstract] [Full Text] [Related]
9. Oncogenic fusions: Targeting Ntrk.
Hagopian G; Nagasaka M
Crit Rev Oncol Hematol; 2024 Feb; 194():104234. PubMed ID: 38122917
[TBL] [Abstract] [Full Text] [Related]
10. ETV6::Ntrk3 gene fusion in a patient with metastatic lung atypical carcinoid successfully treated with repotrectinib: A case report.
Gao L; Ai X; Lu S
Lung Cancer; 2024 Jan; 187():107443. PubMed ID: 38113652
[TBL] [Abstract] [Full Text] [Related]
11. A case of a shrunken multilocular mediastinal cyst that developed into thymic carcinoma with lung metastases 13 years later.
Sugai K; Nakaoka K; Tobita R; Kikuchi S; Inoue K; Enokido M; Kiyoshima M
Thorac Cancer; 2024 Jan; 15(1):94-97. PubMed ID: 38018322
[TBL] [Abstract] [Full Text] [Related]
12. Selpercatinib Shifts treatment Paradigm for mtc and NSCLC.
Cancer Discov; 2023 Dec; 13(12):OF8. PubMed ID: 37874126
[TBL] [Abstract] [Full Text] [Related]
13. Identification of dual STRN-Ntrk2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy.
Lin R; Mallick AB; Wang ZX; Brown SA; Lu B; Jiang W
Diagn Pathol; 2023 Oct; 18(1):116. PubMed ID: 37865792
[TBL] [Abstract] [Full Text] [Related]
14. New options and open issues in the management of unresectable stage III and in early-stage NSCLC: A report from an expert panel of Italian medical and radiation oncologists - INTERACTION group.
Catania C; Filippi AR; Sangalli C; Piperno G; Russano M; Greco C; Scotti V; Proto C; Bennati C; Di Pietro Paolo M; Platania A; Olmetto E; Agustoni F; Teodorani N; Agbaje V; Russo A
Crit Rev Oncol Hematol; 2023 Oct; 190():104108. PubMed ID: 37633350
[TBL] [Abstract] [Full Text] [Related]
15. Ntrk fusions in solid tumours: what every pathologist needs to know.
Nguyen MA; Colebatch AJ; Van Beek D; Tierney G; Gupta R; Cooper WA
Pathology; 2023 Aug; 55(5):596-609. PubMed ID: 37330338
[TBL] [Abstract] [Full Text] [Related]
16. Challenges in diagnosis and biomarker testing for RET-altered lung and thyroid cancer care: an international mixed-method study.
Lazure P; Sireci A; Subbiah V; Murray S; Grohé C; Sherman SI; Kelly E; Bubach P; Péloquin S
BMC Med Educ; 2023 Jun; 23(1):410. PubMed ID: 37277734
[TBL] [Abstract] [Full Text] [Related]
17. The host-directed therapeutic imatinib mesylate accelerates immune responses to Mycobacterium marinum infection and limits pathology associated with granulomas.
Cleverley TL; Peddineni S; Guarner J; Cingolani F; Garcia PK; Koehler H; Mocarski ES; Kalman D
PLoS Pathog; 2023 May; 19(5):e1011387. PubMed ID: 37200402
[TBL] [Abstract] [Full Text] [Related]
18. Head-to-Head Comparison of [
Ballal S; Yadav MP; Roesch F; Raju S; Satapathy S; Sheokand P; Moon ES; Martin M; Awarwal S; Tripathi M; Bal C
Thyroid; 2023 Aug; 33(8):974-982. PubMed ID: 37171126
[No Abstract] [Full Text] [Related]
19. Rationale and Design of the Phase II ANTELOPE Study of Atezolizumab, Carboplatin and nab-Paclitaxel vs. Pembrolizumab, Platinum and Pemetrexed in TTF-1 Negative, Metastatic lung Adenocarcinoma (AIO-trk-0122).
Frost N; Bleckmann A; Griesinger F; Grohé C; Janning M; Kollmeier J; Reinmuth N; Sebastian M; Thomas M; Reck M
Clin Lung Cancer; 2023 Sep; 24(6):568-572. PubMed ID: 37169628
[TBL] [Abstract] [Full Text] [Related]
20. Network Pharmacology and Molecular Docking Analysis on Molecular Targets and Mechanisms of Fei Jin Sheng Formula in the treatment of lung cancer.
Zhang YC; Gao WC; Chen WJ; Pang DX; Mo DY; Yang M
Curr Pharm Des; 2023; 29(14):1121-1134. PubMed ID: 37138492
[TBL] [Abstract] [Full Text] [Related]
[Next]
